Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1653505 | 0.91 | TSHR (0.40) | KDM4EALDH1A1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL1654169 | 0.90 | KDM4E (0.41) | KDM4EALDH1A1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL1653484 | 0.89 | KDM4E (0.36) | KDM4EALDH1A1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL1654287 | 0.87 | KDM4E (0.39) | KDM4EALDH1A1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL1654198 | 0.86 | KDM4E (0.35) | KDM4EALDH1A1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL13675258 | 0.85 | KDM4E (0.37) | KDM4EALDH1A1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL1653391 | 0.85 | RAB9A (0.32) | ALDH1A1TSHRRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL12784632 | 0.84 | ALDH1A1 (0.51) | ALDH1A1TSHRSMN1; SMN2NPC1LMNA | |
| SCHEMBL1653508 | 0.81 | NR1H3 (0.31) | ALDH1A1TSHRRAB9ASMN1; SMN2HPGD | |
| SCHEMBL9073033 | 0.81 | ALDH1A1 (0.34) | ALDH1A1TSHRRAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308839-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-8957070-B2 | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-1873144-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-20090247746-A1 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-1873144-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247746-A1 | Fused heterocyclic compound | GCKR, GCK, GPR119 | KDM4E 1299/4885ALDH1A1 372/4885TSHR 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.